Cannformatics Announces Publication of Groundbreaking Study Identifying Cannabis-Responsive™ Biomarkers in Children with Autism Spectrum Disorders
SAN FRANCISCO, December 8, 2021 /PRNewswire/ —
- The results of the study indicate the potential for Cannabis Sensitive Biomarkers as a powerful tool to quantify, at the metabolic level, the benefits of successful medical cannabis treatment in children with ASD.
- The study results also show the potential of cannabis-responsive biomarkers to provide insight into the mechanism of action of medical cannabis treatment, a first step towards improving medical cannabis treatment for people with ASD from all ages and other neurological disorders.
- The article “Cannabis-Responsive Biomarkers: a pharmacometabolomics-based application to assess the impact of medical cannabis treatment on children with ASD” is published and available to read in the journal Cannabis and cannabinoid research and to Cannformatics.com/asd-study.
Canninformatics, an early-stage biotech startup focused on customizing medical cannabis treatment through the identification and application of saliva-based substances Cannabis Sensitive Biomarkers, today announced that the journal Cannabis and cannabinoid research published the results of its observational pilot study on children with ASD. Study participants were boys and girls ages 6 to 12 of various races, ethnicities, and socioeconomic backgrounds whose symptoms spanned the autism spectrum. The study succeeded in identifying a new class of metabolites, cannabis-responsive biomarkers, which objectively quantify the physiological impact of medical cannabis treatment and provide a tool to study the metabolic pathways affected by medical cannabis and CBD. The underlying technology and study methodology was developed by a multidisciplinary team of experts in biochemistry, bioinformatics, data science, neuropsychology, pediatrics, integrative oncology, emergency medicine, and the medical cannabis industry.
“One of our primary goals was to scientifically validate cannabis-responsive biomarkers as a universal measure to assess the impact of cannabis. The publication of this paper achieves that goal and represents over three years of research to develop a technology of biomarkers to objectively determine the impact of commercially available medical cannabis products,” said Itzhak Kurek, PhD, CEO and co-founder of Cannformatics. “Based on the strong results of this study, we are expanding the development of our platform to include chronic neuropathic pain, anxiety, and chemotherapy-induced nausea and vomiting. We are eternally grateful to all participating children and their families who made this work possible.”
“The lack of objective data contributes to the confusion and stigma that patients face when they turn to medical cannabis to improve their well-being and quality of life. Cannabis-responsive biomarkers offer the industry a new set of tools to quantitatively assess the medical impact of legally available cannabis and CBD products,” said Chief Commercial Officer and Co-Founder, Kenneth Epstein. “We felt it was important to publish and publicly share our findings as a demonstration of our commitment to the ASD and medical cannabis communities. We would like to thank our sponsors canniatric and Whole Plant Access for Autism (WPA4A.org) for their generous support of the ASD pilot study. »
Donald Abrams, MD, study co-author, Cannformatics Scientific Advisor and Professor Emeritus of the UCSF School of Medicine, commented, “This study demonstrates that saliva-based cannabis-responsive biomarkers may be a valuable tool for clinicians and researchers to use to assess the impact of medicine This opens up new avenues of medical cannabis research that will undoubtedly help patients and their physicians have more informed conversations about the potential role of medical cannabis in symptom management.
“As a medical cannabis clinician and pediatrician who treats many patients with autism, this study is very exciting because it shows for the first time that the positive results I see with medical cannabis can be confirmed and quantified. with cannabis-responsive biomarkers. The observed changes in these biomarker levels in response to medical cannabis treatment will help clinicians and parents optimize treatment for children with autism,” said Bonni Goldstein, MD, study co-author and clinical advisor to Cannformatics.
About Cannformatics:
Canninformatics is an early-stage biotech startup focused on the development of Cannabis-Responsive™ biomarkers found in saliva for personalized medical cannabis treatment, product development and other applications. The company’s mission is to develop technologies that enable predictable and reproducible science-based medical cannabis treatment to improve health and quality of life. The company is currently launching a study on medical cannabis treatment of chronic neuropathic pain. Patient groups interested in participating in the study can email [email protected] for more information. Cannformatics is headquartered in San Francisco, California. Follow us on Twitter @cannformatics.
SOURCE Canninformatics
